Related Experiment Video
Updated: Feb 8, 2026
Live Imaging of Drug Responses in the Tumor Microenvironment in Mouse Models of Breast Cancer
Published on: March 24, 2013
Drug conjugates-an emerging approach to treat breast cancer
Mahmud Hasan1, Rehana K Leak1, Robert E Stratford2
1Division of Pharmaceutical, Administrative, and Social Sciences Duquesne University Pittsburgh PA USA.
Abstract:
Breast cancer treatment using a single drug is associated with a high failure rate due, in part, to the heterogeneity of drug response within individuals, nonspecific target action, drug toxicity, and/or development of resistance. Use of dual-drug therapies, including drug conjugates, may help overcome some of these roadblocks by more selective targeting of the cancer cell and by acting at multiple drug targets rather than one. Drug-conjugate approaches include linking drugs to antibodies (antibody-drug conjugates), radionuclides (radioimmunoconjugates), nanoparticles (nanoparticle-drug conjugates), or to other drugs (drug-drug conjugates). Although all of these conjugates might be designed as effective treatments against breast cancer, the focus of this review will be on drug-drug conjugates because of the increase in versatility of these types of drugs with respect to mode of action at the level of the cancer cell either by creating a novel pharmacophore or by increasing the potency and/or efficacy of the drugs' effects at their respective molecular targets. The development, synthesis, and pharmacological characteristics of drug-drug conjugates will be discussed in the context of breast cancer with the hope of enhancing drug efficacy and reducing toxicities to improve patient quality of life.
Insights
Dual-drug conjugates offer a promising approach to breast cancer treatment, potentially overcoming single-drug limitations like resistance and toxicity by targeting multiple pathways for enhanced efficacy and improved patient quality of life.
Area of Science:
- Oncology
- Pharmacology
- Drug Development
Background:
- Single-agent breast cancer therapies face high failure rates due to drug resistance, toxicity, and heterogeneous patient responses.
- Targeting multiple molecular pathways and improving drug selectivity are crucial for overcoming these limitations.
Purpose of the Study:
- To review the development, synthesis, and pharmacological characteristics of drug-drug conjugates for breast cancer treatment.
- To explore how drug-drug conjugates can enhance efficacy and reduce toxicity compared to single-drug therapies.
Main Methods:
- Review of existing literature on drug-drug conjugates in breast cancer.
- Analysis of conjugate design strategies, including novel pharmacophore creation and enhanced target interaction.
- Discussion of pharmacological properties and potential clinical applications.
Main Results:
- Drug-drug conjugates offer increased versatility in targeting cancer cells and their molecular targets.
- These conjugates can potentially create novel pharmacophores or increase the potency and efficacy of existing drugs.
- The approach holds promise for enhancing therapeutic outcomes and minimizing side effects.
Conclusions:
- Drug-drug conjugates represent a significant advancement in breast cancer therapeutic strategies.
- This approach has the potential to improve treatment efficacy and reduce patient toxicity, thereby enhancing quality of life.
Related Concept Videos
01:27Emerging Adulthood
02:50Conjugated Proteins
Nucleoproteins are protein complexes that contain nucleic acids, categorized as deoxyribonucleoproteins (DNPs) or ribonucleoproteins (RNPs) respectively. The nucleosome is a typical example of a DNP where nuclear DNA is associated with histone proteins. The major antigen for the Covid-19 virus SARS-CoV is an RNP that is critical...
02:50Conjugated Proteins
01:19Conjugation
01:30Introduction Cardiac Emergencies
01:19Mechanism of Conjugation